The modern medical device sector predominantly functions under a conceptual framework that has persisted for almost a century: the repair model. This model says that when a biological system fails, it may be repaired or compensated for by interventions like drugs or surgery. This method has played a big role in improving life expectancy and making acute disease outcomes better. However, it exhibits fundamental limitations when applied to chronic, systemic, and age-related pathologies, where cumulative tissue damage, structural degeneration, and loss of functional capacity cannot be fully reversed through repair-based interventions alone.

A paradigm shift is now emerging within the longevity biotechnology sector—one that reframes medical intervention from repair to replacement. This conceptual transition carries profound implications for the medical device industry. Whereas the repair model positions devices as tools applied to existing biological systems, the replacement model positions devices as the core infrastructure for manufacturing new biological tissues and organs. This evolution—from devices as therapeutic instruments to devices as production platforms—represents a transformative opportunity for medical device innovation over the coming decades.

From an investment perspective, this shift is already influencing capital allocation across the longevity and regenerative medicine sectors. At Immortal Dragons, our focus on high-impact longevity technologies has provided early visibility into this transition. Companies developing xenotransplantation platforms, 3D bioprinting systems, and advanced organ preservation technologies are not merely advancing new therapeutic modalities; they are establishing entirely new categories of medical device infrastructure. The $8.49 billion invested in longevity biotechnology in 2024—more than double the $4.2 billion deployed in 2023—reflects growing recognition that replacement-based strategies represent a fundamental departure from incremental, repair-oriented approaches.

The Repair-Replacement Dichotomy

Repair versus replacement strategies reflect fundamentally different assumptions about age-related pathology management. Traditional repair medicine means finding a biological part that isn’t working and fixing it or making up for it. Despite being effective for acute conditions and early-stage disease, this approach is limited by tissue quality and integrity. Pharmacological intervention alone cannot fully rehabilitate a chronically diseased kidney, and surgery cannot structurally restore a cirrhotic liver after extensive fibrosis and architectural collapse.

Instead of trying to repair irreparably damaged tissues, replacement strategies replace organs or tissue systems with functional equivalents. Historically, donor scarcity, immunological incompatibility, and organ transplantation logistics limited this approach. However, advances in genetic engineering, tissue engineering, and biomanufacturing have made replacement-based interventions beyond transplantation feasible and scalable.

Investment reasons for this shift are becoming clearer. Repair-based interventions lose benefit as biological systems age. A drug that reduces cardiovascular mortality by 10–15% may extend lifespan by several years, but it cannot restore organ function or reverse cumulative structural damage. Successful organ replacement can restore physiological function to near-baseline levels, extending healthspan by decades. This functional impact difference supports the idea that replacement strategies may be more cost-effective in advanced, age-related disease.

The rise of replacement-focused longevity biotech investment strategies shows this transition. The global regenerative medicine market is expected to grow from $35.47 billion in 2024 to $90 billion by 2030, with a compound annual growth rate of 16.83%. Instead of incremental optimization of existing pharmacological modalities, the intervention landscape is structurally broadening, requiring sophisticated medical device infrastructure to manufacture, preserve, and integrate replacement tissues and organs at scale.

Xenotransplantation: The Near-Term Replacement Solution

Xenotransplantation—the transplantation of genetically engineered animal organs, mostly from pigs, into humans—is the most immediate replacement paradigm application. Well-established clinical rationale stems from structural organ supply shortages. In the US, over 100,000 patients are on transplant waiting lists, and only 20,000–22,000 donor organs are available annually. In renal disease, this imbalance is severe. Globally, two million people suffer from end-stage renal disease, but donor kidney availability is insufficient, leading to prolonged dialysis dependence, increased mortality, and high healthcare costs.

Clinical Progress: From Concept to Reproducible Outcomes

The xenotransplantation field reached a critical inflection point in 2024-2025, transitioning from isolated proof-of-concept demonstrations to reproducible clinical outcomes. Two companies—eGenesis and United Therapeutics—have received FDA clearance for formal clinical trials, marking the transition from compassionate-use cases to systematic evaluation.

eGenesis completed three porcine kidney transplants under expanded access protocols between December 2024 and June 2025, marking the first evidence of reproducible clinical outcomes in xenotransplantation. Among these cases, the most advanced involved Tim Andrews, a 67-year-old patient who received an EGEN-2784 kidney on January 25, 2025, at Massachusetts General Hospital. As of seven months post-transplant, Mr. Andrews represents the longest-surviving recipient of a genetically engineered porcine-derived solid organ. Previously dependent on dialysis for more than two years, he has since maintained renal function without the need for dialysis.

Another patient, Bill Stewart (54), was transplanted on June 14, 2025, and discharged a week later. Post-transplant follow-up showed functional graft performance without dialysis, confirming reproducibility and short-term viability.

EGEN-2784’s Phase 1/2/3 trial, enrolling 33 patients (3 in Part 1, 30 in Part 2), was approved by the FDA in September 2025. EGEN-2784 has 69 genetic modifications: three glycan antigens are removed to prevent hyperacute immune rejection, seven human transgenes are inserted to regulate immune response and improve coagulation compatibility, and endogenous porcine retroviruses are inactivated for safety. The registration trial supports a mid-2029 regulatory filing.

Want information like this delivered directly to your inbox? Sign up for MPO’s The Source eNewsletter!

United Therapeutics received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance in February 2024 for its UKidney program, which utilizes a porcine kidney engineered with ten genetic modifications, including the insertion of six human genes and the inactivation of four porcine genes. The first patient enrolled in the EXPAND clinical trial (NCT06878560) underwent transplantation at NYU Langone Health on November 18, 2025.

The EXPAND study is structured as a combined Phase 1/2/3 clinical trial, initially enrolling six patients with predefined criteria for expansion to up to 50 participants. If clinical safety and efficacy benchmarks are met, the trial is intended to support a future Biologics License Application (BLA) submission to the FDA.

These developments represent a fundamental shift: xenotransplantation is no longer a speculative technology but an advancing clinical reality with defined regulatory pathways and measurable patient outcomes. The xenotransplantation market is projected to reach $26 billion by 2032, representing a compound annual growth rate of 7.13%.

Implications for Medical Device Infrastructure

However, this market projection captures only the value of the xenotransplanted organs themselves. The true opportunity for the medical device industry extends far beyond the organ, encompassing an entirely new ecosystem of manufacturing, preservation, implantation, and monitoring technologies required to support xenotransplantation at scale.

The Medical Device Ecosystem: From Tools to Manufacturing Infrastructure

The replacement paradigm fundamentally reconceptualizes the role of medical devices. In traditional transplantation, devices serve ancillary functions: surgical instruments facilitate the procedure, perfusion machines preserve organ viability, and monitoring devices track outcomes. In the emerging replacement paradigm, medical devices become the primary infrastructure through which replacement organs are manufactured, preserved, transported, and integrated into the recipient’s biological system.

This transition can be understood across three dimensions:

1. Functional Transition: Medical devices evolve from tools that assist human operators to autonomous or semi-autonomous biomanufacturing systems. In this framework, a perfusion machine is no longer a passive preservation device applied to a donor organ; it becomes a foundational element of ex vivo organ manufacturing infrastructure, supporting continuous metabolic function, conditioning, and quality assessment prior to implantation.
2. Capital Allocation Transition: Capital investment shifts away from consumable, single-use surgical instruments toward capital-intensive, durable manufacturing platforms. Hospitals and transplant centers move from recurrent procurement of disposable devices to long-term acquisition of sophisticated biomanufacturing systems that require significant upfront investment, ongoing maintenance, and multi-year capital planning.
3. Supply Chain Transition: Medical device manufacturers transition from serving decentralized hospital procurement departments to supporting centralized organ manufacturing and processing facilities. As replacement medicine scales, the primary customer base shifts from individual clinical sites to consolidated biomanufacturing centers operating under Good Manufacturing Practice (GMP) standards, fundamentally altering distribution models, service requirements, and regulatory engagement.

Organ Preservation and Perfusion Technologies

Bioproducts from xenotransplantation are time sensitive. Traditional static cold storage limits organ preservation to four to six hours for most organs. This constraint limits transplantation programs’ geographic reach and logistical flexibility.

Normothermic perfusion systems, an emerging medical device, continuously perfuse organs with oxygenated, nutrient-rich solutions at physiological temperatures. Complex pumping, temperature control, and gas exchange systems maintain organ function during long preservation periods. Recent advances have extended preservation windows to 24 hours or longer, revolutionizing organ transplantation logistics.

The organ preservation and perfusion products market was worth 295.6 million in 2025 and is expected to reach 555 million by 2025, growing 6.5% annually. The normothermic machine perfusion segment—the most advanced preservation technology—was worth $1.71 billion in 2024 and is growing rapidly as xenotransplantation programs scale.

This presents a strategic opportunity for medical device manufacturers: as xenotransplantation moves from isolated clinical cases to systematic programs involving hundreds of patients annually, demand for advanced perfusion systems will rise. These passive preservation systems are becoming active biomanufacturing tools for modifying organs outside the body, quality assessment, and conditioning before implantation.

Surgical Integration and Implantation Devices

The anatomical differences between porcine and human organs necessitate novel surgical approaches and specialized instrumentation. Xenotransplanted pig hearts are substantially smaller than human hearts and possess different coronary artery anatomy. Porcine kidneys, while anatomically similar to human kidneys, require modified vascular anastomosis techniques due to variations in renal artery and vein architecture.

Robotic surgical systems tailored to xenotransplantation, integrating real-time imaging, precise manipulation capabilities, and haptic feedback, represent significant opportunities for medical device manufacturers. Furthermore, remote surgical guidance and augmented reality visualization systems can support surgeons with limited experience in these procedures, enabling broader adoption across transplant centers as xenotransplantation programs expand.

Immunosuppression Delivery and Biosensing

Immunosuppression after transplantation is still the most important factor in graft survival. Systemic drug administration in conventional regimens causes significant off-target toxicity and limits long-term tolerability. Implantable drug delivery devices release immunosuppressants locally—either continuously or in response to immunological signals detected by biosensors—reducing systemic exposure and improving graft stability and durability.

Implantable biosensing platforms that detect organ function in real time are exciting new possibilities. Electrochemical sensors can detect tissue injury markers like creatinine, troponin, and lactate dehydrogenase; oxygen sensors can assess perfusion adequacy; and immunological sensors can detect early rejection signals like donor-derived cell-free DNA and cytokine profiles. Clinicians could detect pathological processes in real time and prevent graft damage with wireless data transmission.

Implantable cardiac monitors and continuous glucose monitoring can be extended to xenotransplanted organs with biosensing and targeted drug delivery. Because it is systematically engineered, xenotransplantation allows sensing and control systems to be integrated during organ development rather than retrofitting.

3D Tissue Biofabrication: The Long-Term Replacement Infrastructure

Xenotransplantation solves the immediate problem of not having enough organs by transplanting organs from one species to another. 3D tissue biofabrication, on the other hand, is the long-term goal for replacement medicine: making organs from the patient’s own cells, which means that the body won’t reject them.

The fundamental challenge in engineering functional tissues has been vascularization—establishing nutrient and oxygen delivery networks capable of supporting cell survival in thick tissue constructs. Tissues thicker than approximately 200 micrometers cannot rely on passive diffusion; they require embedded vascular networks to sustain cellular metabolism. This limitation has historically constrained tissue-engineered constructs to thin, avascular structures unsuitable for whole-organ replacement.

SWIFT Technology and Advances in Vascular Bioprinting

Recently developed 3D bioprinting has solved this tissue engineering problem. This technique, developed at Harvard’s Wyss Institute for Biologically Inspired Engineering, allows direct fabrication of vascular networks in dense, living cell matrices. First, stem-cell-derived organ building blocks (OBBs) are assembled into a compact tissue matrix with 200 million cells per milliliter. Next, a fine nozzle prints a sacrificial gelatin-based ink through the matrix to define a perfusable channel network. Controlled heating to 37°C compacts tissue and dissolves gelatin, leaving hollow vascular channels in living tissue.

This method produces tissue constructs nearly an order of magnitude thicker than before and with cellular viability over six weeks. SWIFT allows autologous cell-derived patient-specific tissues, eliminating immunological incompatibility.

Based on this platform, the Wyss Institute introduced coaxial SWIFT (co-SWIFT) in 2024 to create structured blood vessels with endothelial and smooth muscle cell layers that mimic native human vasculature. This method enabled researchers to create patient-specific left coronary artery networks within functional human cardiac tissue, proving the viability of engineering complex, organ-specific vascular architectures.

The 3D Bioprinting Market and Device Opportunities

The 3D bioprinted human tissue market was valued at 2.58-2.81 billion in 2024 and is projected to reach 6.2-9.2 billion by 2035, representing a compound annual growth rate of 12.6-20.5%. Notably, patent filings in the bioprinting field increased by 40% in 2024, reflecting intensifying innovation and commercial activity.

For the medical device industry, 3D tissue biofabrication creates an entirely novel category of manufacturing infrastructure:

• Clinical-Grade Bioprinters: Current bioprinters are primarily research tools. Clinical translation requires high-throughput, reliable systems with automated quality control and GMP compliance. Extrusion-based printing dominates (41% market share in 2025), while laser-assisted printing grows fastest due to higher resolution and improved cell viability. Real-time imaging, automated calibration, and continuous monitoring are essential for clinical-scale production.
• Bioreactor Systems: Tissue maturation depends on bioreactors that maintain controlled microenvironments over weeks, integrating oxygen and pH sensors, perfusion pumps, and mechanical stimulation. These platforms are critical as bioprinted tissues transition from lab prototypes to clinical products.
• Microfluidic Perfusion Systems: Microfluidic systems accurately supply nutrients and oxygen to developing tissues, simulating dynamic physiological conditions to improve maturation, metabolic stability, and functional integration in contrast to static culture.
• Non-Invasive Tissue Assessment Devices: Pre-implantation quality control relies on non-destructive monitoring. Electrical impedance spectroscopy assesses cellular viability and barrier function; optical coherence tomography provides high-resolution structural imaging; and metabolic monitoring tracks oxygen consumption, lactate, and glucose as indicators of tissue health.

The Investment Thesis: Replacement as Strategic Imperative

The emerging emphasis on replacement strategies within longevity biotechnology reflects a fundamental reassessment of the optimal approach to managing age-related pathology. Traditional biotech investment has focused upon drug discovery—interventions operating at the molecular level to modulate disease processes. This approach faces inherent limitations: drugs cannot restore lost tissue architecture, cannot replace non-functional organs, and cannot reverse decades of accumulated cellular damage.

Replacement-focused investment theses recognize these limitations and redirect capital toward technologies that can fundamentally restore tissue and organ function. This reorientation is evident in recent funding data: the longevity biotechnology sector received 8.49 billion in capital investment in 2024, more than double the 4.2 billion invested in 2023. The replacement-focused technologies—xenotransplantation platforms, 3D bioprinting systems, and the medical device infrastructure supporting them—receive a substantial portion of this capital.

Implications for the Medical Device Industry

The transition from repair to replacement represents a fundamental reconceptualization of the medical device industry’s role within healthcare. Historically, medical devices have served as tools applied to biological systems. The replacement paradigm sees devices as the main way to make and deliver new tissues and organs.

This transition creates multiple categories of opportunity for medical device innovation:

• Manufacturing Infrastructure: Companies developing clinical-grade bioprinting systems, bioreactors, and tissue maturation systems will capture substantial market share in the emerging tissue biofabrication sector. The 3D bioprinting market alone is projected to reach $6.2-9.2 billion by 2035, with the fastest growth occurring in technologies enabling vascularized, thick tissue constructs suitable for organ-scale applications.
• Preservation and Transport: The xenotransplantation market, which is expected to reach $26 billion by 2032, needs advanced perfusion systems, portable preservation devices, and real-time monitoring systems. The normothermic machine perfusion market, currently valued at 171 billion, will expand substantially as xenotransplantation programs scale and as bioprinted organs require ex vivo maturation and conditioning prior to implantation.
• Surgical Integration: Specialized surgical instruments, robotic systems, and intraoperative imaging systems tailored to xenotransplantation and tissue implantation represent a distinct market segment. As xenotransplantation moves from specialized academic centers to broader transplant networks, demand for standardized, user-friendly surgical platforms will increase.
• Post-Implant Monitoring: Implantable biosensing systems, wireless monitoring devices, and real-time alert systems enable early detection of graft dysfunction and rejection. These technologies will transition from research prototypes to clinical standards of care as xenotransplantation and bioprinted organ implantation become routine procedures.
• Immunomodulation: Implantable drug delivery systems, localized immunosuppression devices, and tolerance-inducing technologies address the immunological challenges inherent in replacement medicine. While systemic immunosuppression will remain standard in the near term, targeted delivery systems capable of reducing off-target toxicity represent a significant opportunity as the field matures.

Successfully developing these technologies will position companies to lead the medical device industry in the coming decades. The market opportunity is substantial: the xenotransplantation market alone is projected to exceed up to 26 billion by 2031, the 3D bioprinting market is expected to reach 6.2-9.2 billion by 2035, and the broader regenerative medicine market is projected to reach $90 billion by 2030. These projections reflect not speculative forecasts but systematic growth driven by advancing clinical capabilities, expanding patient populations, and maturing regulatory frameworks.

Conclusion

The medical device industry is currently experiencing a significant shift. The century-old model of repair, which focuses on fixing damaged biological systems, has built-in problems when it comes to treating complex, systemic, and age-related diseases. A new paradigm is evolving, driven by progress in xenotransplantation, 3D tissue biofabrication, and regenerative medicine, and supported by more money coming in from biotechnology companies that focus on longevity.

This change makes medical devices more than just helpful tools; they are now the main infrastructure for producing, conserving, and delivering functioning replacement tissues and organs. Now, manufacturers, suppliers, and innovators have the potential to transform healthcare delivery by shifting from repair-based treatments to scalable, replacement-focused medicine.

The future of medicine doesn’t depend on small advancements; it depends on replacing broken biological systems with fully working ones in a planned way. The medical device industry can provide the basic infrastructure that will support regenerative medicine for decades by leading this change. This will have a big impact on patients and create a lot of economic opportunities.

Boyang Wang is the founder of Immortal Dragons, a longevity fund based in Singapore. He holds a Bachelor’s degree in Computer Science from the National University of Singapore and attended Yale University for graduate studies in Computer Science before leaving to pursue entrepreneurship. Prior to founding Immortal Dragons, he established several technology startups. He also currently serves as a senior venture fellow at Healthspan Capital.